Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

G Edan, D Miller, M Clanet, C Confavreux, O Lyon-Caen, C Lubetzki, B Brochet, I Berry, Y Rolland, J C Froment, E Cabanis, M T Iba-Zizen, J M Gandon, H M Lai, I Moseley and O Sabouraud

Department of Neurology, Centre Hospitalier Universitaire, Rennes, France.

OBJECTIVE: To evaluate the efficiency of mitoxantrone in multiple sclerosis. METHODS: Forty two patients with confirmed multiple sclerosis, selected as having a very active disease on clinical and MRI criteria were randomised to receive either mitoxantrone (20 mg intravenously (IV) monthly) and methylprednisolone (1 g iv monthly) or methylprednisolone alone over six months. In the steroid alone group five patients dropped out due to severe exacerbation. RESULTS: Blinded analysis of MRI data showed significantly more patients with no new enhancing lesions in the mitoxantrone group compared with the steroid alone group, (90% v 31%, P < 0.001). In the mitoxantrone group there was a month by month decrease almost to zero in the number of new enhancing lesions, and in the total number of enhancing lesions, whereas both remained high in the steroid alone group. The differences were significant for both indices at all months from 1-6. Unblinded clinical assessments showed a significant improvement in change in EDSS at months 2-6 in the mitoxantrone group, with a final mean improvement of more than one point (-1.1 v + 0.3; P < 0.001). There was a significant reduction in the number of relapses (7 v 31; P < 0.01), and an increase in the number of patients free of exacerbation (14 v 7; P < 0.05). CONCLUSION: In this selected group of patients with multiple sclerosis with very active disease, mitoxantrone combined with methylprednisolone was effective in improving both clinical and MRI indices of disease activity over a period of six months whereas methylprednisolone alone was not. Further double blinded long term studies are needed to properly evaluate the effect of mitoxantrone on progression in disability.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Rieckmann, P., Traboulsee, A., Devonshire, V., Oger, J. (2008). Review: Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 181-192 [Abstract]  
• Furby, J, Hayton, T, Anderson, V, Altmann, D, Brenner, R, Chataway, J, Hughes, R., Smith, K., Miller, D., Kapoor, R (2008). Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler 14: 1068-1075 [Abstract]  
• Vollmer, T, Panitch, H, Bar-Or, A, Dunn, J, Freedman, M., Gazda, S., Campagnolo, D, Deutsch, F, Arnold, D. (2008). Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14: 663-670 [Abstract]  
• Lebrun, C., Debouverie, M., Vermersch, P., Clavelou, P., Rumbach, L., de Seze, J., Wiertlevski, S., Defer, G., Gout, O., Berthier, F., Danzon, A. (2008). Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 14: 399-405 [Abstract]  
• Le Page, E., Leray, E., Taurin, G., Coustans, M., Chaperon, J., Morrissey, S. P, Edan, G. (2008). Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry 79: 52-56 [Abstract] [Full Text]  
• Cocco, E., Marchi, P., Sardu, C., Russo, P., Paolillo, A., Mascia, M., Solla, M., Frau, J., Lorefice, L., Massole, S., Floris, G., Marrosu, M. (2007). Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 13: 975-980 [Abstract]  
• Debouverie, M., Taillandier, L., Pittion-Vouyovitch, S., Louis, S., Vespignani, H. (2007). Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment. Mult Scler 13: 626-631 [Abstract]  
• Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., Kim, H. J., Bar-Or, A. (2007). Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis. J. Immunol. 178: 6092-6099 [Abstract] [Full Text]  
• Choudry, B. A., Chan, J. W. (2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20: 167-180 [Abstract]  
• Paul, F, Dorr, J, Wurfel, J, Vogel, H-P, Zipp, F (2007). Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 78: 198-200 [Full Text]  
• Kopadze, T., Dehmel, T., Hartung, H.-P., Stuve, O., Kieseier, B. C. (2006). Inhibition by Mitoxantrone of In Vitro Migration of Immunocompetent Cells: A Possible Mechanism for Therapeutic Efficacy in the Treatment of Multiple Sclerosis. Arch Neurol 63: 1572-1578 [Abstract] [Full Text]  
• Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., Napoli, S. Q., Sharma, J., Feichter, J., Bakshi, R. (2006). Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (devic disease).. Arch Neurol 63: 957-963 [Abstract] [Full Text]  
• Minden, S L, Frankel, D, Hadden, L, Perloff, J, Srinath, K P, Hoaglin, D C (2006). The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 12: 24-38 [Abstract]  
• Smith, D R, Weinstock-Guttman, B, Cohen, J A, Wei, X, Gutmann, C, Bakshi, R, Olek, M, Stone, L, Greenberg, S, Stuart, D, Orav, J, Stuart, W, Weiner, H (2005). A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 11: 573-582 [Abstract]  
• Frohman, E. M., Stuve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R., Sorensen, P. S., Phillips, J. T., Weinshenker, B., Hawker, K., Hartung, H.-P., Steinman, L., Zamvil, S., Cree, B. A. C., Hauser, S., Weiner, H., Racke, M. K., Filippi, M. (2005). Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations. Arch Neurol 62: 1519-1530 [Abstract] [Full Text]  
• Krapf, H., Morrissey, S. P., Zenker, O., Zwingers, T., Gonsette, R., Hartung, H. -P., the MIMS Study Group, (2005). Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial. Neurology 65: 690-695 [Abstract] [Full Text]  
• Jeffery, D. R, Chepuri, N., Durden, D., Burdette, J. (2005). A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11: 296-301 [Abstract]  
• Saccardi, R., Mancardi, G. L., Solari, A., Bosi, A., Bruzzi, P., Di Bartolomeo, P., Donelli, A., Filippi, M., Guerrasio, A., Gualandi, F., La Nasa, G., Murialdo, A., Pagliai, F., Papineschi, F., Scappini, B., Marmont, A. M., for the Italian GITMO-Neuro Intergroup, (2005). Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105: 2601-2607 [Abstract] [Full Text]  
• Lo, A. C, Hadjimichael, O., Vollmer, T. L (2005). Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 11: 33-40 [Abstract]  
• Rizvi, S. A., Agius, M. A. (2004). Current approved options for treating patients with multiple sclerosis. Neurology 63: S8-S14 [Abstract] [Full Text]  
• Rizvi, S. A., Zwibel, H., Fox, E. J. (2004). Mitoxantrone for multiple sclerosis in clinical practice. Neurology 63: S25-S27 [Abstract] [Full Text]  
• Cohen, B. A., Khan, O., Jeffery, D. R., Bashir, K., Rizvi, S. A., Fox, E. J., Agius, M., Bashir, R., Collins, T. E., Herndon, R., Kinkel, P., Mikol, D. D., Picone, M. A., Rivera, V., Tornatore, C., Zwibel, H. (2004). Identifying and treating patients with suboptimal responses. Neurology 63: S33-S40 [Abstract] [Full Text]  
• Jeffery, D. R. (2004). Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 63: S41-S46 [Abstract] [Full Text]  
• Stuart, W. H., Vermersch, P. (2004). Concomitant therapy for multiple sclerosis. Neurology 63: S28-S34 [Abstract] [Full Text]  
• Debouverie, M, Vandenberghe, N, Morrissey, S P, Anxionnat, R, Pittion-Vouyovitch, S, Vespignani, H, Edan, G (2004). Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Mult Scler 10: 407-412 [Abstract]  
• Stuve, O., Kita, M., Pelletier, D., Fox, R. J, Stone, J., Goodkin, D. E, Zamvil, S. S (2004). Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler 10: S58-S61 [Abstract]  
• Laplaud, D.-A., Ruiz, C., Wiertlewski, S., Brouard, S., Berthelot, L., Guillet, M., Melchior, B., Degauque, N., Edan, G., Brachet, P., Damier, P., Soulillou, J.-P. (2004). Blood T-cell receptor {beta} chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain 127: 981-995 [Abstract] [Full Text]  
• Stuve, O., Kita, M., Pelletier, D., Fox, R. J, Stone, J., Goodkin, D. E, Zamvil, S. S (2004). Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler 10: S58-S61 [Abstract]  
• Goodin, D.S., Arnason, B.G., Coyle, P.K., Frohman, E.M., Paty, D.W. (2003). The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61: 1332-1338 [Abstract] [Full Text]  
• Nash, R. A., Bowen, J. D., McSweeney, P. A., Pavletic, S. Z., Maravilla, K. R., Park, M.-s., Storek, J., Sullivan, K. M., Al-Omaishi, J., Corboy, J. R., DiPersio, J., Georges, G. E., Gooley, T. A., Holmberg, L. A., LeMaistre, C. F., Ryan, K., Openshaw, H., Sunderhaus, J., Storb, R., Zunt, J., Kraft, G. H. (2003). High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102: 2364-2372 [Abstract] [Full Text]  
• Avasarala, J. R, Cross, A. H, Clifford, D. B, Singer, B. A, Siegel, B. A, Abbey, E. E (2003). Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9: 59-62 [Abstract]  
• Brassat, D., Recher, C., Waubant, E., Le Page, E., Rigal-Huguet, F., Laurent, G., Edan, G., Clanet, M. (2002). Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 59: 954-955 [Abstract] [Full Text]  
• O'Connor, P. (2002). Key issues in the diagnosis and treatment of multiple sclerosis: An overview. Neurology 59: S1-33 [Full Text]  
• Weiner, H L, Cohen, J A (2002). Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 8: 142-154 [Abstract]  
• Herndon, R. M. (2002). Medical Hypothesis: Why Secondary Progressive Multiple Sclerosis Is a Relentlessly Progressive Illness. Arch Neurol 59: 301-304 [Abstract] [Full Text]  
• Burt, R. K., Slavin, S., Burns, W. H., Marmont, A. M. (2002). Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 99: 768-784 [Abstract] [Full Text]  
• Mancardi, G. L., Saccardi, R., Filippi, M., Gualandi, F., Murialdo, A., Inglese, M., Marrosu, M. G., Meucci, G., Massacesi, L., Lugaresi, A., Pagliai, F., Sormani, M. P., Sardanelli, F., Marmont, A. (2001). Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57: 62-68 [Abstract] [Full Text]  
• Khan, O. A, Zvartau-Hind, M., Caon, C., Din, M. U, Cochran, M., Lisak, D., Tselis, A. C, Kamholz, J. A, Garbern, J. Y, Lisak, R. P (2001). Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7: 185-188 [Abstract]  
• Bryant, J, Clegg, A, Milne, R (2001). Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?. J. Neurol. Neurosurg. Psychiatry 70: 574-579 [Abstract] [Full Text]  
• Bagnato, F, Tancredi, A, Richert, N, Gasperini, C, Bastianello, S, Bash, C, McFarland, H, Pozzilli, C, Frank, J A (2000). Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study. Mult Scler 6: 43-49 [Abstract]  
• Smith, P. F, Darlington, C. L (1999). Recent developments in drug therapy for multiple sclerosis. Mult Scler 5: 110-120 [Abstract]  
• Koudriavtseva, T, Pozzilli, C, Fiorelli, M, Gasperini, C, Bagnato, F, Galgani, S, Frontoni, M, Ciccarelli, O, Bastianello, S (1998). Determinants of Gd-enhanced MRI response to IFN-{beta}-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 4: 403-407 [Abstract]  
• Molyneux, P D, Tofts, P S, Fletcher, A, Gunn, B, Robinson, P, Gallagher, H, Moseley, I F, Barker, G J, Miller, D H (1998). Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. J. Neurol. Neurosurg. Psychiatry 65: 42-47 [Abstract] [Full Text]  
• Tubridy, N, Ader, H J, Barkhof, F, Thompson, A J, Miller, D H (1998). Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. J. Neurol. Neurosurg. Psychiatry 64: 50-55 [Abstract] [Full Text]  
• Smith, D. R., Weiner, H. L. (1997). Immunologic Aspects of Neurologic and Neuromuscular Diseases. JAMA 278: 1956-1961 [Abstract]